A sterility assurance level (SAL) is the probability that a single unit remains non-sterile after a sterilisation process. The accepted benchmark for terminally sterilised products is 10⁻⁶, or no more than one viable microorganism in a million units. In Australia, the Therapeutic Goods Administration (TGA) requires terminally sterilised biologicals to be validated to a maximal SAL of 10⁻⁶. For research peptides, this figure is rarely a property of the vial itself. It is a property of the process behind it, and most lyophilised peptides are not terminally sterilised at all. This article sets out what SAL means, why a sterility test cannot establish it, and which checks a laboratory can reasonably perform on receipt.
What a sterility assurance level actually measures
SAL expresses sterility as a probability rather than a binary state. Microbial inactivation follows an exponential kinetic: each increment of exposure to a lethal agent (heat, radiation, ethylene oxide, filtration) reduces the surviving population by a constant logarithmic factor. Because the decline is exponential, the surviving population approaches zero without reaching it. Absolute sterility is therefore mathematically unreachable, and regulators manage the probability of survivors instead.
The notation is straightforward:
| SAL | Meaning | Typical context |
|---|---|---|
| 10⁻³ | One non-sterile unit in 1,000 | Roughly the confidence level cited for validated aseptic processes using media fills |
| 10⁻⁶ | One non-sterile unit in 1,000,000 | Terminally sterilised sterile medicines and biologicals |
The 10⁻³ figure for aseptic processes is drawn from a patent filing describing media-fill validation limits, so it should be read as an indicative figure and not a regulatory threshold. The 10⁻⁶ benchmark is the formal requirement, and the reasoning behind it is discussed in Kramer's review of the limits of sterility assurance for readers who want the derivation.
Two consequences follow. First, a SAL is a design target for a validated process, established through bioburden estimation and challenge studies, not a result read from a finished vial. Second, the phrase "sterile" on a product page carries no quantitative information unless it names the method and the validation behind it.
Why peptides rarely achieve a terminal SAL of 10⁻⁶
Terminal sterilisation, typically moist heat in an autoclave, subjects the product to conditions that peptide structures do not tolerate. Hydrolysis, deamidation, oxidation and aggregation all accelerate at elevated temperature. Pharmaceutical manufacturers of heat-sensitive formulations frequently choose aseptic processing because the alternative degrades the molecule.
The usual route for a peptide is therefore:
- Solid-phase synthesis and purification by preparative HPLC.
- Dissolution in an appropriate vehicle and sterile filtration through a membrane (commonly 0.22 µm).
- Aseptic filling into pre-sterilised vials.
- Lyophilisation under aseptic conditions, then stoppering and crimping.
In this sequence, sterility is established by the filtration step and maintained by the aseptic environment. The 10⁻⁶ figure does not transfer automatically, because there is no terminal kill step to validate against. Aseptic assurance is demonstrated through media fills, environmental monitoring, personnel qualification and filter integrity testing. A detailed treatment of the filtration step, including membrane selection and peptide adsorption losses, is available in our bench guide to sterile filtration of peptides, and the distinction between the two approaches is covered in sterile versus aseptic: when to use each.
What a sterility test can and cannot show
Pharmacopoeial sterility testing in Australia follows harmonised methods aligned with Ph. Eur. 2.6.1 and USP <71>, using membrane filtration for filterable preparations or direct inoculation for those that are not, with a minimum 14-day incubation. The test detects viable microorganisms that grow in the specified media under the specified conditions.
The limitation is statistical. A passing result means no growth was detected in the sample tested. It is not an absolute guarantee that every unit is sterile. Testing a small number of vials from a large lot has low power to detect low-level contamination. One trade source states that testing alone reaches only about 10⁻² SAL, but because we could not confirm that page, treat the order of magnitude as illustrative: the sample sizes in compendial tests cannot approach a 10⁻⁶ claim.
The TGA's position is consistent with this. Sterility testing should sit within a wider Contamination Control Strategy (CCS) in which facility and process design, validation, and routine monitoring together demonstrate that the process is reliable. Where the test fits in that structure is the subject of our 14-day sterility checklist for lab release.
Sterility is not the only microbiological attribute
A sterile vial can still be unsuitable for a given assay. Endotoxins are lipopolysaccharide fragments from Gram-negative bacterial cell walls. They are heat-stable, survive filtration in part, and persist after the organisms that produced them are dead. Endotoxin contamination is a recognised problem particularly for products from bacterial expression systems such as E. coli, and validated removal steps during purification, for example ion exchange chromatography, are needed because a sterility pass does not address them.
Chemically synthesised peptides carry a lower inherent risk than recombinant products, but endotoxin can enter through water, excipients, or contaminated equipment. For cell-based work, where endotoxin alters cytokine responses and confounds readouts, a bacterial endotoxin result (LAL or recombinant factor C) is a separate and relevant specification. Researchers designing cell culture experiments will find the interaction between COAs, sterility and reproducibility in our note on reproducible peptide protocols for cell culture.
The regulatory position in Australia
The distinction between a regulated therapeutic good and a research chemical is material. SAL requirements in TGA guidance apply to products supplied for human use. The TGA has stated that unapproved peptides in circulation have not been evaluated for safety, quality or effectiveness, and it has raised questions about how such products are manufactured and whether they are sterile. That alert was reported by ABC News on 14 April 2026, and the TGA maintains a dedicated peptide products page for current guidance.
For laboratories, the practical implication is that a research-grade peptide should be treated as a research reagent. Its sterility documentation, where any exists, should be read as a statement about the supplier's process and testing, not as evidence that the vial meets a medicinal SAL of 10⁻⁶. Research peptides are strictly for laboratory use and are not for human or veterinary use. For a risk-based comparison of GMP and research-grade material, see our guide for Australian labs.
Verification on receipt
A laboratory cannot re-establish a SAL on arrival, but it can confirm that the documentation and the physical condition of the material are consistent. The following checks are proportionate.
Documentation
- A batch-specific certificate of analysis (COA) from an independent laboratory, with the batch or lot number matching the vial label.
- Reported identity (mass spectrometry) and purity (HPLC), with the method and date stated.
- Any stated sterility or endotoxin results, with the method (for example USP <71> or a bacterial endotoxin assay) named and the sample size indicated.
- A traceable chain from the lot to the COA. Our six-step batch traceability procedure and three receipt checks set this out.
Physical condition
- Crimp seal intact, stopper seated, no cracks in the glass or visible leakage.
- Lyophilised cake appearance consistent with the COA description, without discolouration, collapse or particulate matter. Common warning signs are listed in our visual inspection guide.
- Packaging temperature history, relevant to peptides with limited ambient stability.
After reconstitution
Once a vial is opened and reconstituted, the supplier's assurance no longer applies to the contents. Contamination risk then depends on bench technique, the diluent, and storage. Aseptic handling in a biological safety cabinet or laminar flow environment, single-use aliquoting, and defined discard criteria are the controls that matter. See aseptic bench handling with COA-verified aliquots and when to discard a contaminated vial.
Disinfection and the limits of surface treatment
A frequent question is whether alcohol treatment of a stopper or work surface achieves sterility. Under the classification devised by Spaulding and reviewed by Rutala and colleagues, disinfection and sterilisation are distinct categories, with sterilisation implying destruction of all microbial life including spores. Wiping a septum with 70% alcohol reduces surface bioburden but does not constitute sterilisation and carries no SAL. It is nonetheless a standard element of aseptic technique and should be treated as one control among several. For peptide-modified materials, ethanol remains the preferred disinfection method because heat and UV can degrade the bioactive component.
Our perspective
We supply research peptides, and we think the sterility conversation in this category is frequently conducted in the wrong terms. A SAL is a validated-process attribute. A supplier of lyophilised research material that states a SAL of 10⁻⁶ without describing a terminal sterilisation step has, at best, used the term loosely. What a laboratory can reasonably ask of a supplier is narrower and more useful: independent third-party testing, a batch-specific COA, and clear statements of what was and was not tested.
Our products are independently third-party tested to a purity above 99%, with a verifiable COA for every batch. Purity by HPLC and sterility are separate attributes, and we do not present one as evidence of the other. We dispatch from Melbourne within one business day, which removes customs transit and reduces the time a vial spends outside controlled storage. Our view is that researchers are best served by reading the COA, matching the lot, inspecting the vial, and applying aseptic technique at the bench, rather than relying on a single label claim.
— Dr. Authur
Research supply from Melbourne
Au Peptide Labs stocks pharmaceutical-grade research peptides across Metabolic & GLP-1, Recovery & Repair, GH Secretagogues, Cognitive & Sleep and Longevity & Cellular categories, along with laboratory supplies including bacteriostatic water, insulin syringes and alcohol wipes. Orders are dispatched from Australia in discreet packaging, and Express Post is available for $10. Custom and bulk orders can be arranged through the online store. All products are for laboratory research only.
Frequently asked questions
What does a sterility assurance level of 10⁻⁶ mean?
It means the validated sterilisation process is designed so that the probability of a single unit remaining non-sterile is no more than one in a million. It is a statistical target for the process, established by validation, and not a measurement taken on each vial. The TGA applies this level to terminally sterilised biologicals.
Does sterile mean there are no microorganisms?
In definition, yes, but in practice it cannot be demonstrated absolutely. Because microbial kill is exponential, regulators accept a very low probability of survivors instead of a guarantee of zero. A passing sterility test shows that nothing grew in the sample tested.
Can a sterility test confirm a SAL for a peptide batch?
No. The compendial test samples a small number of units and cannot demonstrate a one-in-a-million probability. Assurance comes from process validation, environmental monitoring and filter integrity testing, with the test as one confirmatory element.
Is sterile filtration equivalent to terminal sterilisation?
No. Filtration removes microorganisms by size exclusion and is followed by aseptic filling, so sterility depends on maintaining the aseptic environment. It is the usual choice for heat-sensitive peptides, but it is validated differently from an autoclave cycle and does not carry a terminal SAL.
Does a sterile vial also have low endotoxin?
Not necessarily. Endotoxins persist after microorganisms are removed or killed, so they require their own specification and test. This matters most for cell-based assays.
Sources
- TGA: Understanding rules for manufacturing biologicals
- TGA: Manufacture of Sterile Medicines, The Countdown to Annex 1
- TGA: Guidelines for sterility testing of therapeutic goods
- TGA: Peptide products
- ABC News: TGA safety alert on unregulated peptides
- DSDP Analytics: USP <71> Sterility Tests
- Sandle: Removal of endotoxin in pharma processes
- Rutala et al.: Disinfection, sterilization, and antisepsis
- US patent 6566659: pulsed light sterilisation